Ratings by Goldman Sachs (Corinne Jenkins)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/13/2026 | Ideaya Biosciences | IDYA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2026 | Fulcrum Therapeutics | FULC | Maintain | Early-Stage Biotech (N/A) |
|
Details | ||
| 2/10/2026 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 1/29/2026 | Halozyme Therapeutics | HALO | Maintain | Sell (N/A) |
|
Details | ||
| 1/12/2026 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/12/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 12/8/2025 | Fulcrum Therapeutics | FULC | Maintain | Early-Stage Biotech (N/A) |
|
Details | ||
| 12/4/2025 | Halozyme Therapeutics | HALO | Downgrade | Sell (Neutral) |
64.66 (122.50) |
89.45% | Details | |
| 11/17/2025 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 9/30/2025 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 9/17/2025 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2025 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 7/10/2025 | TG Therapeutics | TGTX | New Coverage | Neutral (N/A) |
37.92 (53.30) |
40.56% | Details | |
| 7/10/2025 | Ideaya Biosciences | IDYA | New Coverage | Neutral (N/A) |
22.97 (33.81) |
47.19% | Details | |
| 7/10/2025 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Neutral (N/A) |
34.29 (37.54) |
9.48% | Details | |
| 7/10/2025 | Halozyme Therapeutics | HALO | New Coverage | Neutral (N/A) |
56.58 (64.66) |
14.28% | Details | |
| 7/10/2025 | Roivant Sciences | ROIV | New Coverage | Buy (N/A) |
11.22 (34.70) |
209.27% | Details | |
| 7/10/2025 | Rhythm Pharmaceuticals | RYTM | New Coverage | Buy (N/A) |
89.00 (88.23) |
-0.87% | Details | |
| 12/5/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 11/27/2024 | Alector Inc. | ALEC | Maintain | Sell (N/A) |
|
Details | ||
| 11/21/2024 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/19/2024 | Alector Inc. | ALEC | Maintain | Sell (N/A) |
|
Details | ||
| 11/6/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2024 | TG Therapeutics | TGTX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2024 | Intra-Cellular Therapies | ITCI | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Sell (N/A) |
|
Details | ||
| 10/15/2024 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Sell (N/A) |
|
Details | ||
| 10/3/2024 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 10/2/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Sell (N/A) |
|
Details | ||
| 9/25/2024 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2024 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 9/19/2024 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2024 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2024 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2024 | TG Therapeutics | TGTX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/22/2024 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 7/19/2024 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 7/12/2024 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 6/10/2024 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2024 | Fulcrum Therapeutics | FULC | Upgrade | Buy (Neutral) |
7.47 (3.70) |
-50.47% | Details | |
| 5/10/2024 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 4/17/2024 | Intra-Cellular Therapies | ITCI | Maintain | Neutral (N/A) |
|
Details | ||
| 4/8/2024 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/5/2024 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/2/2024 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2024 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2024 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2024 | Amylyx Pharmaceuticals inc. | AMLX | Downgrade | Neutral (Buy) |
18.97 (6.98) |
-63.21% | Details | |
| 3/8/2024 | Amylyx Pharmaceuticals inc. | AMLX | Downgrade | Neutral (Buy) |
18.97 (27.33) |
44.07% | Details | |
| 2/27/2024 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2024 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 1/25/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 1/25/2024 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 1/25/2024 | Fulcrum Therapeutics | FULC | Maintain | Neutral (N/A) |
|
Details | ||
| 1/24/2024 | Altimmune | ALT | New Coverage | Neutral (N/A) |
10.04 (4.58) |
-54.38% | Details | |
| 1/18/2024 | Intra-Cellular Therapies | ITCI | Maintain | Neutral (N/A) |
|
Details | ||
| 1/18/2024 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 1/9/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Sell (N/A) |
|
Details | ||
| 12/6/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 11/28/2023 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2023 | Ambrx Biopharma | AMAM | Maintain | Neutral (N/A) |
|
Details | ||
| 11/10/2023 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 10/16/2023 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 10/16/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Sell (N/A) |
|
Details | ||
| 9/27/2023 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2023 | Fulcrum Therapeutics | FULC | New Coverage | Neutral (N/A) |
4.09 (3.70) |
-9.54% | Details | |
| 9/25/2023 | Alector Inc. | ALEC | New Coverage | Sell (N/A) |
6.03 (1.95) |
-67.66% | Details | |
| 9/25/2023 | Harmony Biosciences Holdings Inc. | HRMY | Downgrade | Sell (Neutral) |
35.72 (37.54) |
5.1% | Details | |
| 9/13/2023 | Ambrx Biopharma | AMAM | Maintain | Neutral (N/A) |
|
Details | ||
| 9/12/2023 | Geron Corporation | GERN | Upgrade | Buy (Neutral) |
2.45 (1.39) |
-43.27% | Details | |
| 9/11/2023 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2023 | BioXcel Therapeutics | BTAI | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2023 | TG Therapeutics | TGTX | Upgrade | Neutral (Sell) |
10.49 (53.30) |
408.1% | Details | |
| 7/24/2023 | Halozyme Therapeutics | HALO | Downgrade | Neutral (Buy) |
42.57 (122.50) |
187.76% | Details | |
| 7/24/2023 | Amylyx Pharmaceuticals inc. | AMLX | Upgrade | Buy (Neutral) |
22.41 (18.97) |
-15.35% | Details | |
| 7/21/2023 | TG Therapeutics | TGTX | Maintain | Sell (N/A) |
|
Details | ||
| 7/19/2023 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 7/3/2023 | BioXcel Therapeutics | BTAI | Maintain | Neutral (N/A) |
|
Details | ||
| 6/7/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Neutral (N/A) |
|
Details | ||
| 5/26/2023 | BioXcel Therapeutics | BTAI | Maintain | Neutral (N/A) |
|
Details | ||
| 5/24/2023 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
22.25 (33.81) |
51.96% | Details | |
| 5/12/2023 | Geron Corporation | GERN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2023 | Terns Pharmaceuticals | TERN | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2023 | TG Therapeutics | TGTX | Maintain | Sell (N/A) |
|
Details | ||
| 3/28/2023 | Intra-Cellular Therapies | ITCI | Maintain | Neutral (N/A) |
|
Details | ||
| 3/28/2023 | Geron Corporation | GERN | New Coverage | Neutral (N/A) |
2.33 (1.20) |
-48.5% | Details | |
| 3/22/2023 | Altimmune | ALT | Downgrade | Neutral (Buy) |
10.92 (2.23) |
-79.58% | Details | |
| 3/15/2023 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2023 | Rapt Therapeutics | RAPT | Maintain | Buy (N/A) |
|
Details | ||
| 3/7/2023 | Aclaris Therapeutis | ACRS | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2023 | Ambrx Biopharma | AMAM | Maintain | Neutral (N/A) |
|
Details | ||
| 2/21/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/26/2023 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2023 | BioXcel Therapeutics | BTAI | Maintain | Neutral (N/A) |
|
Details | ||
| 1/19/2023 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2023 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 12/29/2022 | TG Therapeutics | TGTX | Maintain | Sell (N/A) |
|
Details | ||
| 12/20/2022 | Altimmune | ALT | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2022 | Terns Pharmaceuticals | TERN | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2022 | BioXcel Therapeutics | BTAI | Upgrade | Neutral (Sell) |
15.18 (0.07) |
-99.54% | Details | |
| 12/1/2022 | Altimmune | ALT | New Coverage | Buy (N/A) |
9.46 (2.23) |
-76.43% | Details | |
| 12/1/2022 | Aclaris Therapeutis | ACRS | New Coverage | Buy (N/A) |
15.79 (3.48) |
-77.96% | Details | |
| 12/1/2022 | Rapt Therapeutics | RAPT | New Coverage | Buy (N/A) |
17.07 (58.02) |
239.89% | Details | |
| 11/9/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Sell (N/A) |
|
Details | ||
| 9/27/2022 | Terns Pharmaceuticals | TERN | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 8/22/2022 | Gritstone Oncology | GRTS | Downgrade | Sell (Neutral) |
4.49 (0.03) |
-99.33% | Details | |
| 8/22/2022 | Intra-Cellular Therapies | ITCI | Downgrade | Neutral (Buy) |
50.74 (131.87) |
159.89% | Details | |
| 8/8/2022 | Rhythm Pharmaceuticals | RYTM | Upgrade | Buy (Neutral) |
18.59 (88.23) |
374.61% | Details | |
| 7/12/2022 | Harmony Biosciences Holdings Inc. | HRMY | Downgrade | Neutral (Buy) |
54.70 (37.54) |
-31.37% | Details | |
| 7/12/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Neutral (N/A) |
|
Details | ||
| 6/23/2022 | Athira Pharma | ATHA | Maintain | Neutral (N/A) |
|
Details | ||
| 5/24/2022 | Rovi Corp. | ROVI | Maintain | Buy (N/A) |
|
Details | ||
| 5/24/2022 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/9/2022 | BioXcel Therapeutics | BTAI | Maintain | Sell (N/A) |
|
Details | ||
| 5/4/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2022 | Ambrx Biopharma | AMAM | New Coverage | Neutral (N/A) |
4.26 (28.00) |
557.28% | Details | |
| 2/25/2022 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2022 | Radius Health | RDUS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/16/2022 | Intra-Cellular Therapies | ITCI | New Coverage | Buy (N/A) |
53.00 (131.87) |
148.81% | Details | |
| 12/15/2021 | Gritstone Oncology | GRTS | New Coverage | Neutral (N/A) |
11.88 (0.03) |
-99.75% | Details | |
| 12/15/2021 | Athira Pharma | ATHA | New Coverage | Neutral (N/A) |
13.17 (6.75) |
-48.75% | Details | |
| 12/15/2021 | Roivant Sciences | ROIV | New Coverage | Buy (N/A) |
8.26 (34.70) |
320.1% | Details | |
| 12/10/2021 | Radius Health | RDUS | Downgrade | Neutral (Buy) |
8.01 (30.00) |
274.53% | Details | |
| 12/1/2021 | BioXcel Therapeutics | BTAI | Maintain | Sell (N/A) |
|
Details | ||
| 11/30/2021 | TG Therapeutics | TGTX | Maintain | Sell (N/A) |
|
Details | ||
| 11/15/2021 | BioXcel Therapeutics | BTAI | Downgrade | Sell (Buy) |
33.05 (0.07) |
-99.79% | Details | |
| 11/4/2021 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2021 | Radius Health | RDUS | Maintain | Buy (N/A) |
|
Details | ||
| 9/14/2021 | Terns Pharmaceuticals | TERN | New Coverage | Buy (N/A) |
11.12 (52.95) |
376.17% | Details | |
| 9/14/2021 | Rhythm Pharmaceuticals | RYTM | New Coverage | Neutral (N/A) |
12.98 (88.23) |
579.74% | Details | |
| 9/14/2021 | Rain Therapeutics | RAIN | New Coverage | Neutral (N/A) |
16.69 (0.63) |
-96.23% | Details | |
| 8/5/2021 | Radius Health | RDUS | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2021 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/22/2021 | Acceleron Pharma | XLRN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/22/2021 | Spring Works Therapeutics | SWTX | New Coverage | Buy (N/A) |
68.20 (46.99) |
-31.1% | Details | |
| 3/22/2021 | Radius Health | RDUS | New Coverage | Buy (N/A) |
21.99 (8.01) |
-63.57% | Details | |
| 3/22/2021 | Acceleron Pharma | XLRN | New Coverage | Neutral (N/A) |
133.58 (178.75) |
33.81% | Details |
